TAK-652,a Novel CCR5 Inhibitor,has Favourable Drug Interactions with other Antiretrovirals in Vitro

Baba M. , Takashima K. , Miyake H. , Kanzaki N. , Teshima K. , Wang X. , Shiraishi M. , & Iizawa Y. TAK-652 inhibits CCR5-mediated HIV-1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrobial Agents and Chemotherapy. In the press.

Chou T.C. The median-effect principle and the combination index for quantitation of synergism and antagonism. In Synergism and Antagonism in Chemotherapy, 1991; pp. 61–102. Edited by Chou T.C. , & Rideout D.C. . San Diego, CA: Academic Press.

Chou T.C. , & Martin N. 2004. CompuSyn for Windows, Multiple-Drug Dose-Effect Analyzer and Manual. Combosyn Paramus, NJ, USA.

Tremblay C.L. , Giguel F. , Kollmann C. , Guan Y. , Chou T.C. , Baroudy B.M. , & Hirsch M.S. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrobial Agents and Chemotherapy 2002; 46: 1336–1339.

Tremblay C. Effects of HIV-1 entry inhibitors in combination. Current Pharmaceutical Design 2004; 10: 1861–1865.

Tremblay C.L. , Giguel F. , Guan Y. , Chou T.C. , Takashima K. , & Hirsch M.S. TAK-220, a novel small molecule CCR5 antagonist, has favorable anti-HIV interactions with other antiretrovirals in vitro. Antimicrobial Agents and Chemotherapy 2005; 49: 3483–3485.

Tremblay C. , Kollmann C. , Giguel F. , Chou T.C. , & Hirsch M.S. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. Journal of Acquired Immune Deficiency Syndrome 2000; 25: 99–102.